Sign In
Buy MEIP
$3.07
+0 (+0%)
At Close: Dec 09, 2025
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'
09:00am, Wednesday, 10'th Sep 2025
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company's exp
[UK, July 24, 2025] - BTC As the blockchain industry enters a new round of market cycle, the multi-currency linkage effect gradually emerges, and the price of BTC today starts to rise at 118875.30. Ac
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy.
Why Is MEI Pharma Stock Soaring On Friday?
01:22pm, Friday, 18'th Jul 2025
MEI Pharma, Inc. MEIP stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
04:05pm, Tuesday, 13'th May 2025
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
04:12pm, Wednesday, 12'th Feb 2025
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is con
MEI Pharma Reports Fiscal Year End 2024 Cash Position
04:01pm, Thursday, 19'th Sep 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the c
MEI Pharma to Consider Strategic Alternatives
08:30am, Monday, 22'nd Jul 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic al
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
02:18pm, Monday, 01'st Jul 2024
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
National Bank of Canada FI Takes $36,000 Position in MEI Pharma, Inc. (NASDAQ:MEIP)
05:07am, Monday, 20'th May 2024
National Bank of Canada FI bought a new stake in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commi
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
10:38am, Tuesday, 14'th May 2024
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible viola
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
08:02am, Thursday, 11'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
08:00am, Wednesday, 10'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
